Market Newsdesk

Oakland, April 05, 2021 (GLOBE NEWSWIRE) — Deem, a leading mobile and cloud technology provider for the corporate travel industry, today announced it has been selected as a 2021 winner of the Best Company Outlook award from Comparably. Winners were chosen from tens of thousands of companies and selected based on anonymous employee feedback provided on the Comparably platform. 

Deem ranks in the top 5% of companies with fewer than 500 employees, based on staff members sharing their outlook, or confidence in the company’s future, and their likelihood of recommending Deem to friends, reflected in their employee net promoter score (eNPS). The high rankings reinforce Deem’s values of winning together, passion and drive, customer centered, and trust and transparency.

“Receiving this award from Comparably affirms the strength of our team and their belief in the travel technology we’re creating together,” said Deem President David Grace. “It also reveals our collective optimism in the travel industry. After an historically challenging year, our team is more passionate than ever about travel and making travel easier for everyone.”

To qualify for a Comparably award, companies must meet a minimum threshold of ratings from employees who have left anonymous public ratings on their company’s Comparably.com page within a 12-month period (March 2020 through March 2021).

About Comparably

Comparably (www.comparably.com) is a leading workplace culture and compensation monitoring site that provides the most comprehensive and accurate representation of what it’s like to work at companies. Employees can anonymously rate their employers in 20 workplace culture categories, providing the public a transparent and in-depth look at the experiences different segments of workers have based on gender, ethnicity, age, department, tenure, location, education and company size. Since launching in 2016, Comparably has accumulated 10 million ratings on 60,000 U.S. companies. The platform has become one of the fastest-growing SaaS solutions for employer branding and a trusted third-party site for workplace and salary data, most notably for its annual Best Places to Work series.

About Deem

Deem is on a mission to transform travel. Starring Etta, its mobile-first, corporate travel booking and management platform, Deem offers employees everything they need to easily make the right travel decisions for themselves and their company. Deem’s travel technology plugs into major travel agencies and expense solution providers, empowering more corporate customers and the world’s largest travel management companies.

Deem is a wholly owned and independently run subsidiary of Enterprise Holdings. The company is headquartered in Oakland, California, with offices in Dublin, Ireland and Bangalore, India. Learn more at Deem.com.

LOS ANGELES, April 05, 2021 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

Tyson Foods, Inc. (NYSE: TSN)
Class Period: March 13, 2020 – December 15, 2020
Lead Plaintiff Deadline: April 5, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Tyson knew, or should have known, that the highly contagious coronavirus was spreading throughout the globe; (2) Tyson did not in fact have sufficient safety protocols to protect its employees in its facilities; (3) as a result, Tyson employees contracted and spread the coronavirus within the facilities; (4) as a result of the foregoing, Tyson would face negative impact to its production, including complete shutdowns of certain facilities; (5) due to the failure to protect its employees, Tyson would suffer financial harm related to its lowered production; and (6) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Clover Health Investments, Corp. (NASDAQ: CLOV, CLOVW)
Class Period: October 6, 2020 – February 4, 2021
Lead Plaintiff Deadline:   April 6, 2021

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company’s Clover Assistant platform was under active investigation by the DOJ for at least 12 issues ranging from kickbacks to marketing practices to undisclosed third-party deals; (2) the DOJ’s investigation presented an existential risk to the Company, since it derives most of its revenues from Medicare; (3) Clover’s sales were driven by a major undisclosed related party deal and misleading marketing targeting the elderly, not its purported “best-in-class” technology; (4) a significant portion of Clover’s sales were by way of an undisclosed relationship between Clover and an outside brokerage firm controlled by Clover’s Head of Sales; and (5) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com

Fort Myers, Fla., April 05, 2021 (GLOBE NEWSWIRE) — Florida Cancer Specialists & Research Institute (FCS) is pleased to welcome Charmion Patton, EdD, PHR as Senior Vice President of People & Culture. In this newly created role, Dr. Patton will oversee the development of strategic and innovative culture initiatives to attract, engage and develop the FCS workforce, encompassing recruitment, organizational design, performance management, total rewards and HR compliance. She will also serve as the company’s Diversity & Inclusion Officer.  

“Dr. Patton will play a critical role in advancing our FCS commitment to becoming an employer of choice,” said FCS CEO Nathan H. Walcker. “In partnership with executive and senior leaders, she will help ensure that our business decisions and actions set the stage for team member success and engagement.”

“What stood out to us about Dr. Patton is that she is an inspiring and transformational leader,” added Joyce Nelson, FCS Chief Administrative Officer. “She is well suited to lead our strategic initiatives that will further strengthen our culture and team member experience and cultivate expanded opportunities for personal and professional growth.”  

Dr. Patton joins FCS with 20 years of leadership-level experience that has spanned a range of national and international organizations. Most recently, she served as Director of Human Resources for Planned Parenthood of Northern California and Vice President, Human Resources & Education at Dignity Health- Mercy Medical Center.  In her prior roles, Dr. Patton provided strategic HR leadership and counsel in positions of increasing responsibility with Seton Medical Center of Verity Health System in Daly City, CA and with Price Waterhouse Coopers in San Francisco, CA, as well as other health care systems and physician groups along the Pacific coast.

Dr. Patton holds a Doctorate in Education with a focus on Organizational Development & Leadership from Grand Canyon University in Phoenix, AZ, where she earned her MS in Leadership & Culture Change as a Deans Honor Recipient from the Ken Blanchard College of Business. She holds a Bachelor of Arts in Management & Human Relations from Trevecca Nazarene University in Nashville, TN.  

 Her numerous professional certifications include Professional Human Resources (PHR), Benefits Administration and collective bargaining negotiations.  

# # #

 
About Florida Cancer Specialists & Research Institute
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. Over the past 5 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, MD Anderson, and Memorial Sloan Kettering, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.

Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies, and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians, and staff.

*Prior to approval

Attachment

• Dr. Charmion Patton for PRESSER

LOS ANGELES, April 05, 2021 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

bluebird bio, Inc. (NASDAQ: BLUE)
Class Period:  May 11, 2020 – November 4, 2020
Lead Plaintiff Deadline: April 13, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) data supporting bluebird’s BLA submission for LentiGlobin for SCD was insufficient to demonstrate drug product comparability; (2) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company’s BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (3) as a result of all the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

EHang Holdings Limited (NASDAQ: EH)
Class Period: December 12, 2019 – February 16, 2021
Lead Plaintiff Deadline: April 19, 2021

Shareholders with $10,000 losses or more are encouraged to contact the firm

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company’s purported regulatory approvals in Europe and North America for its EH216 were for use as a drone, and not for carrying passengers; (2) its relationship with its purported primary customer is a sham; (3) EHang has only collected on a fraction of its reported sales since its ADS began trading on NASDAQ in December 2019; (4) the Company’s manufacturing facilities were practically empty and lacked evidence of advanced manufacturing equipment or employees; and (5) as a result, Defendants’ statements about its business, operations, and prospects were materially false and misleading and/or lacked reasonable basis at all relevant times.

Jianpu Technology, Inc. (NYSE: JT)
Class Period: May 29, 2018 – February 16, 2021
Lead Plaintiff Deadline: April 19, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that certain of the Company’s transactions carried out by the Credit Card Recommendation Business Unit involved undisclosed relationships or lacked business substance; (2) that, as a result, Jianpu’s revenue and costs and expenses for fiscal 2018 and 2019 were overstated; (3) that there were material weaknesses in Jianpu’s internal control over financial reporting; (4) that, as a result of the foregoing, the Company’s fiscal 2018 Form 20-F was reasonably likely to be restated; and (5) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com.  If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com

LOS ANGELES, April 05, 2021 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

Immunovant, Inc. (NASDAQ: IMVT)
Class Period: October 2, 2019 – February 1, 2021
Lead Plaintiff Deadline: April 20, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) HSAC had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401; (2) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating TED and WAIHA; (3) the foregoing foreseeably diminished IMVT-1401’s prospects for regulatory approval, commercial viability, and profitability; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Ebix, Inc. (NASDAQ: EBIX)
Class Period: November 9, 2020 – February 19, 2021
Lead Plaintiff Deadline: April 23, 2021

Throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that there was insufficient audit evidence to determine the business purpose of certain significant unusual transactions in Ebix’s gift card business in India during the fourth quarter of 2020; (2) that there was a material weakness in the Company’s internal controls over the gift or prepaid revenue transaction cycle; and (3) that the Company’s independent auditor was reasonably likely to resign over disagreements with Ebix regarding $30 million that had been transferred into a commingled trust account of Ebix’s outside legal counsel; and (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Apache Corporation (NASDAQ: APA)
Class Period: September 7, 2016 – March 13, 2020
Lead Plaintiff Deadline: April 26, 2021

Shareholders with $400,000 losses or more are encouraged to contact the firm

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Apache intentionally used unrealistic assumptions regarding the amount and composition of available oil and gas in Alpine High; (2) Apache did not have the proper infrastructure in place to safely and/or economically drill and/or transport those resources even if they existed in the amounts purported; (3) these misleading statements and omissions artificially inflated the value of Apaches operations in the Permian Basin; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

MultiPlan Corporation f/k/a Churchill Capital Corp. III (NYSE: MPLN)
Class Period: July 12, 2020 – November 10, 2020
Lead Plaintiff Deadline: April 26, 2021

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that MultiPlan was losing tens of millions of dollars in sales and revenues to Naviguard, a competitor created by one of MultiPlan’s largest customers, UnitedHealthcare, which threatened up to 35% of MultiPlan’s sales and 80% of its levered cash flows by 2022; (2) that sales and revenue declines in the quarters leading up to the Merger were not due to “idiosyncratic” customer behaviors as represented, but rather due to a fundamental deterioration in demand for MultiPlan’s services and increased competition, as payors developed competing services and sought alternatives to eliminating excessive healthcare costs; (3) that MultiPlan was facing significant pricing pressures for its services and had been forced to materially reduce its take rate in the lead up to the Merger by insurers, who had expressed dissatisfaction with the price and quality of MultiPlan’s services and balanced billing practices, causing MultiPlan to cut its take rate by up to half in some cases; (4) that, as a result of the foregoing, MultiPlan was set to continue to suffer from revenues and earnings declines, increased competition and deteriorating pricing dynamics following the Merger; (5) that, as a result of the foregoing, MultiPlan was forced to seek continued revenue growth and to improve its competitive positioning through pricey acquisitions, including through the purchase of the healthcare technology company HST for $140 million at a premium price from a former MultiPlan executive only one month after the Merger; and (6) that, as a result of the foregoing, Churchill III investors had grossly overpaid for the acquisition of MultiPlan in the Merger, and MultiPlan’s business was worth far less than represented to investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com.   If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com

SAN MATEO, Calif., April 05, 2021 (GLOBE NEWSWIRE) — Jupiter, the global leader in climate analytics for resilience and risk management, announced today that industry veteran Marc Lehmann had joined the company as Head of Business Development and Partnerships – UK/Europe. In his new role, Lehmann will spearhead Jupiter’s ongoing expansion in UK/European markets.

“European multinationals are sophisticated when it comes to climate-related risk,” said Rich Sorkin, CEO of Jupiter. “Marc’s deep expertise in insurance and cat risk in European markets and track record of growing new businesses make him the ideal person to guide Jupiter’s first wave of geographic expansion outside of the United States, building on our existing relationships with Zurich Insurance Group, BP and several others across the continent.”

Prior to joining Jupiter, Lehmann served as Director within the Climate Risk and Decarbonization Strategy group at KPMG in London, following several senior level roles within the insurance sector including Head of Client Service Development at AIG, and Global Head of Catastrophe Risk Management for corporate clients at Willis Towers Watson.

“Climate change continues to dominate the risk agenda at board level for many major corporate and financial services organisations in the UK/Europe and there is an ever growing need for focused analytics to help firms identify, quantify and manage these risks,” Lehmann said. “Nobody is addressing physical climate risk as comprehensively and effectively as Jupiter, which is why I’m so thrilled to be joining them now.”

About Jupiter

Jupiter is the global market, science, and technology leader in physical climate analytics for risk management and resiliency planning. Its analytics are used across the private and public sectors: customers include at least one of the world’s five largest firms in asset management, banking, chemicals, insurance, minerals and mining, oil and gas, reinsurance, pharmaceuticals, and power—as well as critical departments and agencies within both the United States government and climate-change-vulnerable geographies around the world. Jupiter’s ClimateScore™ Intelligence Platform provides sophisticated, dynamic, hyper-local, current- hour-to-50-plus-year probabilistic risk analysis for weather in a changing climate. The company’s FloodScore™, HeatScore™, WindScore™, FireScore™, and ClimateScore Global™ services are used for climate-related risk assessment and management worldwide. Jupiter’s models are based on the latest science, as developed by the global Earth and Ocean Systems science community.

Jupiter offers commercial services to asset owners in critical infrastructure, financial services including insurance, banking and asset management, energy and real estate, and the public sector. These customers use Jupiter services for a broad range of applications, including capital planning, risk management, site selection, design requirements, supply chain management, investment and asset valuations, and shareholder disclosures. For more information, please visit jupiterintel.com.

Media Contact:

Hugh Moore
Broadsheet Communications
202-471-0661
[email protected]

TORONTO, April 05, 2021 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) notes the statement released by Papua New Guinea prime minister James Marape announcing an imminent agreement to reopen Porgera mine. Barrick and the Government of Papua New Guinea have continued to hold constructive discussions on a framework agreement for the recommissioning of Porgera, which has been on care and maintenance since April 2020.

The agreement under discussion is in line with the principles announced in October, providing for a joint venture between Barrick Niugini Limited (BNL) and the government of PNG to operate Porgera going forward on the basis of increased PNG ownership and a fair sharing of economic benefits. BNL would continue as the operator of the mine. We remain hopeful that we will reach agreement with the PNG Government on a long-term partnership that will see the reopening of Porgera in the near future.

A further statement will be issued once a final agreement is achieved.

About Porgera

The Porgera Joint Venture is an open pit and underground gold mine located at an altitude of 2,200-2,600 metres in the Enga Province of Papua New Guinea, about 600 kilometres north-west of Port Moresby.  BNL is a joint venture company in which Barrick and Zijin Mining Group each own 50%.

Enquiries:

Kathy du Plessis
Investor and Media Relations
+44 20 7557 7738
Email: [email protected]

Website:
www.barrick.com

Cautionary Statement on Forward-Looking Information

Certain information contained or incorporated by reference in this press release, including any information as to our strategy, projects, plans or future financial or operating performance, constitutes “forward-looking statements”. All statements, other than statements of historical fact, are forward-looking statements. The words “progress”, “negotiations”, “imminent”, “continue”, “discussion”, “expect”, “will”, “would”, “remain”, “future” and similar expressions identify forward-looking statements. In particular, this press release contains forward-looking statements including, without limitation, with respect to: the statement released by Papua New Guinea Prime Minister James Marape announcing an imminent agreement to reopen the Porgera mine; the status of discussions with the government of Papua New Guinea to reopen the Porgera mine and resume production in line with the agreement in principle announced in October 2020, and the expected terms and timeline to finalize the proposed framework agreement; the duration of the temporary suspension of operations at Porgera; Barrick and BNL’s response to the government of Papua New Guinea’s decision not to extend Porgera’s special mining lease; and expectations regarding financial performance and other outlook or guidance.

Forward-looking statements are necessarily based upon a number of estimates and assumptions including material estimates and assumptions related to the factors set forth below that, while considered reasonable by the Company as at the date of this press release in light of management’s experience and perception of current conditions and expected developments, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Known and unknown factors could cause actual results to differ materially from those projected in the forward-looking statements and undue reliance should not be placed on such statements and information. Such factors include, but are not limited to: fluctuations in the spot and forward price of gold, copper or certain other commodities (such as silver, diesel fuel, natural gas and electricity); the speculative nature of mineral exploration and development; changes in mineral production performance, exploitation and exploration successes; risks associated with projects in the early stages of evaluation and for which additional engineering and other analysis is required; disruption of supply routes which may cause delays in construction and mining activities at Barrick’s more remote properties; diminishing quantities or grades of reserves; increased costs, delays, suspensions and technical challenges associated with the construction of capital projects; operating or technical difficulties in connection with mining or development activities, including geotechnical challenges and disruptions in the maintenance or provision of required infrastructure and information technology systems; failure to comply with environmental and health and safety laws and regulations; non-renewal of key licences by governmental authorities, including non-renewal of Porgera’s Special Mining Lease; changes in national and local government legislation, taxation, controls or regulations and/or changes in the administration of laws, policies and practices; expropriation or nationalization of property and political or economic developments in Papua New Guinea; timing of receipt of, or failure to comply with, necessary permits and approvals; lack of certainty with respect to foreign legal systems, corruption and other factors that are inconsistent with the rule of law; risks associated with illegal and artisanal mining; risks associated with new diseases, epidemics and pandemics, including the effects and potential effects of the global Covid-19 pandemic; damage to the Company’s reputation due to the actual or perceived occurrence of any number of events, including negative publicity with respect to the Company’s handling of environmental matters or dealings with community groups, whether true or not; the possibility that future exploration results will not be consistent with the Company’s expectations; risks that exploration data may be incomplete and considerable additional work may be required to complete further evaluation, including but not limited to drilling, engineering and socioeconomic studies and investment; risk of loss due to acts of war, terrorism, sabotage and civil disturbances; litigation; contests over title to properties, particularly title to undeveloped properties, or over access to water, power and other required infrastructure; business opportunities that may be presented to, or pursued by, the Company; risks associated with working with partners in jointly controlled assets; employee relations including loss of key employees; increased costs and physical risks, including extreme weather events and resource shortages, related to climate change; and availability and increased costs associated with mining inputs and labor. In addition, there are risks and hazards associated with the business of mineral exploration, development and mining, including environmental hazards, industrial accidents, unusual or unexpected formations, pressures, cave-ins, flooding and gold bullion, copper cathode or gold or copper concentrate losses (and the risk of inadequate insurance, or inability to obtain insurance, to cover these risks).

Many of these uncertainties and contingencies can affect our actual results and could cause actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, us. Readers are cautioned that forward-looking statements are not guarantees of future performance. All of the forward-looking statements made in this press release are qualified by these cautionary statements. Specific reference is made to the most recent Form 40-F/Annual Information Form on file with the SEC and Canadian provincial securities regulatory authorities for a more detailed discussion of some of the factors underlying forward-looking statements and the risks that may affect Barrick’s ability to achieve the expectations set forth in the forward-looking statements contained in this press release.

We disclaim any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.